ViiV Healthcare presents a new podcast about the Power of Being Seen

 
 

ViiV Healthcare announces its new weekly podcast Being Seen an in-depth exploration of the role culture plays in resolving how we see ourselves and how we are seen by others. Hosted and narrated by Darnell Moore award-winning writer and activist, the first season explores current cultural representations of the queer and gay Black male experience and the impact on their lives and society. Being Seen is available October 6 th wherever you get your podcasts and at www.beingseenpodcast.com .

 

Through conversations with leading artists, writers, activists, entertainers, and community leaders including; writer, director, and producer Lee Daniels and Ben Cory Jones ; Samira Nasr , Editor-in-Chief at Harper's Bazaar, and activist, writer, George M. Johnson , ViiV Healthcare hopes Being Seen encourages the creation of more accurate cultural portrayals of the queer and gay Black male experience in order to reduce stigma and change perception - impacting everything from HIV to institutional inequality.

 

"There is nothing else like Being Seen in the podcast universe for Black gay and queer men – it's a safe space and platform for them to express themselves, share their experiences, and bare their souls and identities freely and uncensored," said Marc Meachem , head of US External Affairs for ViiV Healthcare.  "We think it will reduce stigma and bring hope to Black gay and queer men who may find their story in the stories being shared on the podcast and know they are not alone, they are being seen – and we hope it encourages them to write or tell their own story even if it's just for themselves."

 

The project has been enriched and informed by creative consultants and partners Emil Wilbekin founder of Native Son; DaShawn Usher founder of MOBI; Emmy winning producer Darius Brown ; Photographers Gioncarlo Valentine and Texas Isaiah – both of whom served as curators for Being Seen photography. As well as the incredible group of illustrators and photographers who either licensed work or created original work to help bring the project to life visually and through sound.  Theme music for the podcast is Colouour by Moses Sumney .

 

"Being Seen podcast is another medium through which the lives of Black queer and trans men are uplifted and centered. Our contributions to culture matter. The work that so many of us do on behalf Black people matters" said Darnell Moore . "And we have to share our stories, as different and complex as they may be, to push back against the erasure of our work and voices. I hope that audiences end every episode a bit more committed to co-creating a world where the lives of all Black people matter."

 

ViiV's evolving commitments to communities in the US most disproportionately impacted by HIV, and the reality of current times have motivated support of this new cultural collaboration.

 

"Our sole focus on HIV and the HIV community for more than 10 years has given ViiV clear insights into the importance of listening and hearing the community – and we are committed to amplifying those voices through our work" said Lynn Baxter , Head of North America , ViiV Healthcare. " Being Seen brings awareness to the impact of stigma on every aspect of these individual's lives and spotlights the obligation everyone has to end discrimination against marginalized communities, including people living with HIV."

 

  Being Seen expands on the insights and findings from landmark ethnographic research conducted by ViiV Healthcare, exploring the lives of Black gay men in Baltimore, Maryland , and Jackson, Mississippi.  This research uncovered that these men wanted the freedom to create their own experiences and live without labels. It also gave life to the ground-breaking experiential theater piece As Much As I Can , created and produced by Harley & Co and presented by ViiV Healthcare.

 

  Being Seen is produced by Harley & Co. and Darnell Moore and created in partnership with ViiV Healthcare.

 
 

  Artwork by Ronald Jackson 

 
 

  About Darnell Moore – Being Seen host and producer  

 

  Darnell L. Moore is an award-winning writer, activist, organizer, and author of No Ashes in the Fire: Coming of Age Black and Free in America. He is Director of Inclusion Strategy for Content & Marketing at Netflix, editor-at-large at CASSIUS and co-managing editor at The Feminist Wire. A prolific writer, Darnell has been published in various media outlets including MSNBC, The Guardian, Huffington Post, EBONY, The Root, The Advocate, OUT Magazine, VICE and others, as well as numerous academic journals. He received the Humanitarian Award from the American Conference on Diversity for his LGBTQ advocacy and has been named among EBONY Magazine's Power 100, Time Out New York's Eight LGBT Influencers, The Root 100, and Planned Parenthood's Top 99 Dream Keepers.

 

  About Harley & Co –   Being Seen Producer  

 

Harley & Co. is a New York based creative studio that produces award-winning multi-platform social justice and culture projects such as activist experiential theater, "As Much As I Can." Their work has won numerous awards including Cannes Lions, AD&D, Shorty for Social Good and most recently, Fast Company's World Changing Ideas. Harley & Co. has been featured in the NYTimes, Teen Vogue, NBC, ABC and Bloomberg, among others, for their unique creative design and approach.

 

  About ViiV Healthcare  

 

ViiV Healthcare is the only pharmaceutical company solely focused on combating, preventing, and ultimately curing HIV and AIDS.  We exist to make sure no one living with HIV and AIDS is left behind, and we are 100% dedicated to addressing the challenges of the HIV epidemic. Our portfolio ambition is to make HIV a smaller part of people lives.  Beyond developing innovative medicines, ViiV Healthcare works with communities to address enduring disparities in HIV care and outcomes.

 

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012 . The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

 

For more information on the company, its management, portfolio, pipeline and commitment, please visit https://viivhealthcare.com/en-gb/ .

 

  About GSK  

 

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com .

 

  Cautionary statement regarding forward-looking statements  

 

 

 

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK's Principal risks and uncertainties section of the Q2 Results and any impacts of the COVID-19 pandemic.

 

 

 

 

 
 

   

 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/viiv-healthcare-presents-a-new-podcast-about-the-power-of-being-seen-301143992.html  

 

SOURCE ViiV Healthcare

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×